Trulicity Cost in Massachusetts 2026

What Does Trulicity Actually Cost in Massachusetts in 2026?

The manufacturer list price for Trulicity is $931 per month regardless of dose, and that number has held steady across Massachusetts retail pharmacies in early 2026. Cash-pay patients who walk into a CVS, Walgreens, or independent pharmacy in Boston, Worcester, or Springfield without any discount program will face that full price. In practice, very few patients pay it.

The actual out-of-pocket cost depends on three variables: insurance status, tier placement on the formulary, and whether the patient qualifies for manufacturer assistance. Each variable can move the number dramatically. A patient on a commercial PPO with Trulicity on Tier 3 might pay $80-$150 per fill after a copay. A patient on MassHealth who clears prior authorization pays nothing at the pharmacy counter. A cash-pay patient who activates the Lilly Insulin Value Program savings card drops to $25 per month if they meet income criteria.

The REWIND trial (N=9,901, Lancet 2019) established dulaglutide's cardiovascular benefit, which is one reason payers take the drug seriously enough to keep it on formulary rather than excluding it outright. That clinical weight matters when arguing for coverage in Massachusetts.

The FDA-approved prescribing information for Trulicity lists the available doses as 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg, all delivered as a prefilled single-dose pen. All four dose strengths carry the same list price per pen unit, so escalating from 0.75 mg to 4.5 mg does not change the monthly cost under most formulary arrangements.

How MassHealth (Massachusetts Medicaid) Covers Dulaglutide

MassHealth covers Trulicity for type 2 diabetes management, but prior authorization is required. The authorization criteria follow a step-therapy protocol: most MassHealth managed care plans require documentation that the patient has tried and either failed or had a contraindication to metformin before approving a GLP-1 receptor agonist. Some plans additionally require an HbA1c threshold, typically 7.5% or above, though that threshold can vary by managed care entity (MCE).

Massachusetts runs MassHealth through several MCEs, including Tufts Health Together, Boston Medical Center HealthNet Plan, and Fallon Total Care. Each MCE administers its own prior authorization process, but all operate under the MassHealth Drug List (Pharmaceutical Benefit), which designates dulaglutide as a covered product with PA. Prescribers submit PA requests through the MCE's online portal or by fax; turnaround is typically 3-10 business days.

Once approved, MassHealth members pay $0 at the pharmacy for a 30-day supply. The program does not require brand-name substitution to a biosimilar because no FDA-approved dulaglutide biosimilar has reached the market as of early 2026.

The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists as preferred agents in patients with type 2 diabetes and established cardiovascular disease, which strengthens a PA appeal if the initial request is denied on a formulary-management basis. Prescribers writing PA appeals should cite both the ADA standards and the REWIND cardiovascular outcome data.

A practical PA checklist for Massachusetts prescribers:

1. Document metformin trial (or contraindication) in the chart.
2. Record the most recent HbA1c with date.
3. Note any cardiovascular disease, chronic kidney disease (eGFR), or heart failure diagnosis.
4. Submit the MCE-specific PA form with the above documentation attached.
5. Follow up by day 5 if no response has been received.

Commercial Insurance Coverage in Massachusetts

Most large commercial insurers operating in Massachusetts, including Blue Cross Blue Shield of MA, Tufts Health Plan, Harvard Pilgrim, and Aetna, include Trulicity on their formularies, typically at Tier 3 or Tier 4. Tier placement determines copay, and copays range from roughly $60 to $200 per month before any savings card is applied.

The FDA label for dulaglutide carries two approved indications: glycemic control in type 2 diabetes and reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Insurers that applied step-therapy exclusively to the diabetes indication often have a separate pathway for the CV-risk indication, which can bypass the metformin-first requirement.

Step therapy is common. Blue Cross Blue Shield of MA typically requires a trial of a lower-cost GLP-1 (usually generic or lower-tier) before approving Trulicity, unless the prescriber documents a clinical reason the preferred agent cannot be used. Massachusetts law under M.G.L. Chapter 175, Section 47AA provides a step-therapy override right: if a patient's prescribing physician certifies that the required step-therapy drug is clinically inappropriate, the insurer must grant an exception within 72 hours for non-urgent cases and 24 hours for urgent ones.

Patients who are denied coverage can file an internal appeal and, if that fails, an external appeal through the Massachusetts Health Insurance Consumer Assistance Program. The program is free and handled by the Center for Health Information and Analysis.

The Eli Lilly Savings Card and Other Manufacturer Programs

Eli Lilly runs two patient assistance programs relevant to Massachusetts residents.

Lilly Cares Foundation Patient Assistance Program. Uninsured or underinsured patients whose household income falls at or below 400% of the federal poverty level may qualify for free Trulicity through this program. Applications are submitted at lillycares.com. Processing typically takes 2-4 weeks for initial enrollment. The program provides a 12-month supply with annual reapplication.

Lilly Savings Card (commercially insured). Eligible patients who have commercial insurance and are not enrolled in a government-funded program (Medicare, Medicaid, CHIP, TRICARE) can use the savings card to pay as little as $25 per month. The card is activated at insulinaffordability.com or through the Lilly app. The card covers the gap between the insurance copay and $25, up to an annual savings cap that Lilly updates each year.

Patients on MassHealth are not eligible for the commercial savings card because that card cannot be used with Medicaid plans. They rely entirely on MassHealth coverage. Patients on Medicare Part D similarly cannot use the manufacturer card due to federal anti-kickback provisions, though they may benefit from Medicare's $35/month cap on insulin (note: the $35 cap applies to insulin, not GLP-1 agonists, so Trulicity is not covered under that specific provision).

A 2022 JAMA Internal Medicine analysis found that manufacturer savings cards substantially reduced out-of-pocket costs for patients with commercial insurance but did not reduce total drug spending, because list prices remained elevated. This is worth understanding: the card helps individual patients but does not address the underlying pricing structure.

Is Compounded Dulaglutide Legal in Massachusetts?

Compounded dulaglutide is legal in Massachusetts when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The key regulatory distinction is between 503A pharmacies (patient-specific compounding, licensed by the Massachusetts Board of Pharmacy) and 503B outsourcing facilities (bulk compounding, FDA-registered). Massachusetts residents can receive compounded dulaglutide from a licensed 503A pharmacy.

The FDA's guidance on compounded drug products clarifies that compounding from bulk active pharmaceutical ingredients is permitted for 503A pharmacies when the drug is not commercially available in the required strength or formulation, or when a documented patient need exists. Dulaglutide is not on the FDA's 503A Bulks List as of early 2026, which means the legal basis for compounding is narrower than it was for semaglutide during the shortage period.

Prescribers should note that the FDA removed semaglutide from its drug shortage list in 2024, and dulaglutide has not appeared on that list. Without a recognized shortage designation, the legal footing for bulk-API compounding of dulaglutide is less clear than it was for semaglutide. Patients and prescribers should verify the current status with the compounding pharmacy's pharmacist-in-charge before initiating a prescription.

Cost for compounded dulaglutide from a 503A pharmacy varies by pharmacy and formulation but is generally substantially lower than the $931 list price. Some Massachusetts-licensed compounding pharmacies quote $150-$350 per month for patient-specific formulations, though these prices shift frequently.

The Massachusetts Board of Pharmacy maintains the list of licensed compounding pharmacies operating in the state. Patients should confirm licensure before filling any compounded prescription.

Getting Trulicity via Telehealth in Massachusetts

Telehealth prescribing of Trulicity is permitted in Massachusetts. Massachusetts enacted permanent telehealth coverage requirements through M.G.L. Chapter 175, Section 47BB, which requires commercial insurers to cover services delivered via telehealth on the same basis as in-person services (parity). Prescribers licensed in Massachusetts may prescribe Trulicity via a synchronous video visit after an appropriate clinical evaluation.

Federal DEA rules on controlled substances via telehealth do not apply to Trulicity because dulaglutide is not a scheduled controlled substance. This means none of the prescribing restrictions that complicated remote prescribing of buprenorphine or stimulants apply here.

A telehealth prescriber must still conduct a standard clinical evaluation before initiating Trulicity: review of HbA1c, assessment of cardiovascular risk, kidney function (eGFR), contraindications (personal or family history of medullary thyroid carcinoma, MEN 2), and current medications. The FDA prescribing information carries a black-box warning for thyroid C-cell tumors based on rodent data; this must be discussed during the prescribing visit regardless of whether it occurs in person or via video.

HealthRX offers telehealth visits for Massachusetts residents and can connect patients with a licensed MA prescriber for initial evaluation and ongoing management of dulaglutide therapy. Prescriptions are sent to the patient's preferred pharmacy or to a licensed compounding pharmacy if clinically appropriate and legally permissible at the time of prescribing.

Clinical Evidence Supporting Dulaglutide Use

Prescribers and patients asking about cost-effectiveness need to understand the underlying evidence base. Dulaglutide's formulary position and insurance coverage in Massachusetts rest substantially on two bodies of data: glycemic efficacy and cardiovascular outcome data.

AWARD trial program. The AWARD series (AWARD-1 through AWARD-8) established dulaglutide's HbA1c-lowering efficacy across a range of comparators including insulin glargine, exenatide, sitagliptin, and metformin. AWARD-6 (N=599, published in Diabetes Care) showed dulaglutide 1.5 mg was non-inferior to semaglutide 0.5 mg (the trial predated higher semaglutide doses) in HbA1c reduction at 26 weeks: mean change of -1.42% vs. -1.36% (P<0.001 for non-inferiority).

REWIND cardiovascular outcome trial. REWIND (N=9,901, median follow-up 5.4 years, Lancet 2019) randomized patients with type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors to dulaglutide 1.5 mg weekly vs. placebo. The primary composite outcome (non-fatal MI, non-fatal stroke, or CV death) occurred in 12.0% of dulaglutide patients vs. 13.4% of placebo patients, a 12% relative risk reduction (HR 0.88; 95% CI 0.79-0.99; P=0.026). This trial directly underpins the FDA's cardiovascular risk reduction indication added in 2020.

Kidney outcomes. A pre-specified secondary analysis of REWIND (published in Lancet Diabetes and Endocrinology, 2021) found that dulaglutide reduced a composite kidney outcome (sustained decline in eGFR of 40% or more, end-stage kidney disease, or death from kidney disease) by 15% vs. placebo (HR 0.85; 95% CI 0.77-0.93; P=0.0004). This renal data informs prescribing decisions for Massachusetts patients with diabetic kidney disease.

Weight effects. Dulaglutide produces modest weight loss compared to higher-dose semaglutide formulations. In REWIND, mean body weight decreased by approximately 3 kg in the dulaglutide arm vs. 1 kg in placebo over 5.4 years. Patients seeking primarily weight loss may be better served by semaglutide 2.4 mg (Wegovy), which produced 14.9% mean body weight reduction in STEP-1 (N=1,961, NEJM 2021) vs. 2.4% placebo. Dulaglutide's strength is glycemic control combined with cardiovascular protection, not maximal weight loss.

Comparing Trulicity Costs to Other GLP-1 Options in Massachusetts

Massachusetts patients and prescribers choosing among GLP-1 receptor agonists should understand where Trulicity sits on the cost spectrum.

| Agent | List Price/Month | Key Differentiator | |---|---|---| | Dulaglutide (Trulicity) | $931 | Once-weekly; CV outcome data | | Semaglutide SC (Ozempic) | $996 | Greater HbA1c and weight reduction | | Semaglutide oral (Rybelsus) | $935 | Daily oral; lower bioavailability | | Liraglutide (Victoza) | $722 | Daily injection; longest market history | | Semaglutide 2.4 mg (Wegovy) | $1,349 | FDA-approved for weight management | | Tirzepatide (Mounjaro) | $1,069 | Dual GIP/GLP-1; superior HbA1c reduction |

List prices across this class are within roughly $200-$400 of each other, so the cost decision for most insured Massachusetts patients comes down to formulary tier placement rather than list price. Patients should call their insurer's member services line and ask specifically which GLP-1 agents are on Tier 2 or Tier 3 on their current formulary.

The American Association of Clinical Endocrinology (AACE) 2022 Consensus Statement on type 2 diabetes management designates GLP-1 receptor agonists with cardiovascular outcome trial data as preferred agents for patients with atherosclerotic cardiovascular disease, and dulaglutide qualifies under that designation alongside liraglutide and semaglutide.

Practical Steps for Massachusetts Patients in 2026

Getting Trulicity at the lowest possible cost in Massachusetts involves working through a short sequence of steps.

Check your formulary first. Log into your insurer's member portal or call the number on your insurance card and ask which GLP-1 receptor agonists are covered and at what tier. If Trulicity is on Tier 4 and semaglutide is on Tier 3, that difference may be $80-$120 per month.

If you have commercial insurance, activate the Lilly savings card before your first fill. The card can be activated online at insulinaffordability.com and presented at the pharmacy. It brings the copay to $25/month for eligible patients.

If you are on MassHealth, ask your prescriber to submit the prior authorization at the time of the visit. Bring your most recent lab results (HbA1c, eGFR, lipids) to speed the documentation process. Most MCEs accept electronic PA submissions through their portals, which is faster than fax.

If you are uninsured, apply to the Lilly Cares Foundation before paying cash. Processing takes 2-4 weeks, so ask your prescriber for a short-supply bridge prescription if you need to start therapy immediately.

Telehealth is a valid pathway. You do not need to see an endocrinologist in person to get a Trulicity prescription in Massachusetts. A licensed telehealth prescriber can evaluate you, order baseline labs, and send the prescription to your preferred pharmacy in a single video visit.

A 2023 analysis of GLP-1 adherence patterns published in Diabetes Care found that out-of-pocket cost was the single strongest predictor of early discontinuation among commercially insured patients with type 2 diabetes, with each $50 increase in monthly cost associated with a 9% increase in discontinuation risk. Reducing cost friction at initiation is clinically meaningful, not just financially convenient.